COVID-19患者弥漫性肺血栓的全身性低剂量阿替普酶治疗
Systemic reduced-dose alteplase for diffuse pulmonary thrombi in a COVID-19 patient.
作者信息
Colkesen Yucel
机构信息
Department of Cardiology Erdem Hospital Istanbul Turkey.
出版信息
Clin Case Rep. 2023 Mar 15;11(3):e7116. doi: 10.1002/ccr3.7116. eCollection 2023 Mar.
Abstract
Pulmonary embolism has a high frequency in COVID-19 patients admitted to the intensive care unit. Low level of fibrinolysis is one of the asserted contributors to a prothrombotic state in COVID-19. Thrombotic coagulopathy is mostly encountered as diffuse pulmonary thrombi. Diffuse pulmonary microemboli was treated successfully with reduced dose thrombolysis.
摘要
在入住重症监护病房的新冠肺炎患者中，肺栓塞的发生率很高。纤维蛋白溶解水平低是新冠肺炎患者血栓前状态的公认促成因素之一。血栓性凝血病大多表现为弥漫性肺血栓。弥漫性肺微栓塞通过降低剂量的溶栓治疗获得成功。
Zotero 插件